| ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma H Verdaguer, T Saurí, DA Acosta, M Guardiola, A Sierra, J Hernando, ... Clinical Cancer Research 28 (8), 1662-1671, 2022 | 32 | 2022 |
| Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation Q Serra-Camprubí, H Verdaguer, W Oliveros, N Lupión-Garcia, ... Clinical Cancer Research 29 (2), 432-445, 2023 | 4 | 2023 |
| Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer L Pascual‐Reguant, Q Serra‐Camprubí, D Datta, D Cianferoni, S Kourtis, ... EMBO Molecular Medicine 15 (12), e18459, 2023 | 1 | 2023 |
| LOXL 2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells G Serra‐Bardenys, E Blanco, C Escudero‐Iriarte, Q Serra‐Camprubí, ... The FEBS Journal 291 (11), 2423-2448, 2024 | | 2024 |
| Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models M Yáñez-Bartolomé, Q Serra-Camprubí, EJ Arenas, M Escorihuela, ... Patient-Derived Xenografts: Methods and Protocols, 139-151, 2024 | | 2024 |
| A journey towards the identification of novel therapeutical strategies for advanced cholangiocarcinoma with IDH1 mutations Q Serra Camprubí Universitat de Barcelona, 2023 | | 2023 |
| Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer LP Reguant, TV Tian, D Datta, D Cianferoni, S Kourtis, A Gañez-Zapater, ... European Journal of Cancer 174, S61-S62, 2022 | | 2022 |
| The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer L Pascual-Reguant, TV Tian, D Datta, D Cianferoni, S Kourtis, ... bioRxiv, 2022.05. 27.493725, 2022 | | 2022 |
